NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine

Obesity

Volumn 15, Issue 8, 2007, Pages 2027-2042

  Erondu, Ngozi ^a   Addy, Carol ^a   Lu, Kaifeng ^a   Mallick, Madhuja ^a   Musser, Bret ^a   Gantz, Ira ^a   Proietto, Joseph ^b   Astrup, Arne ^c   Toubro, Søren ^c   Rissannen, Aila M ^d   Tonstad, Serena ^e   Haynes, William G ^f   Gottesdiener, Keith M ^a   Kaufman, Keith D ^a   Amatruda, John M ^a   Heymsfield, Steven B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

BMI; Neuropeptide Y; Obesity treatment; Overweight; Sibutramine

Indexed keywords

EID: 34548618969     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.242     Document Type: Article

References (53)

1. Hogan S, FIeury A, Hadvary P, et al. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obes. 1987;11(Suppl 3): 35-42.
2. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20:270-9.
3. Hadvary P, Sidler W, Meister W, Vetter W, Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem. 1991;266:2021-7.
4. Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta. 1988;962:308-16.
5. Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004;5:633-42.
6. Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets. 2005;6:201-13.
7. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
8. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5:51-68.
9. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-46.
10. Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet. 2004;17:293-316.
11. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;3:CD004094.
12. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology. 1984;115:427-9.
13. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev. 1999;20:68-100.
14. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661-71.
15. Sawchenko PE. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J Comp Neurol. 1998;402:435-41.
16. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999;22:221-32.
17. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 1996;382:168-71.
18. Hu Y, Bloomquist BT, Cornfield LJ, et al. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem. 1996;271:26315-9.
19. Criscione L, Rigollier P, Batzl-Hartmann C, et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest. 1998;102:2136-45.
20. Cabrele C, Langer M, Bader R, et al. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem. 2000;275:36043-8.
21. Parker EM, Balasubramaniam A, Guzzi M, et al. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides. 2000;21:393-9.
22. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol. 2001;60:534-40.
23. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, Heyer D. Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept. 2002;106:47-54.
24. Mashiko S, Ishihara A, Iwaasa H, et al. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology. 2003;144:1793-801.
25. Sato N, Takahashi T, Shibata T, et al. Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists. J Med Chem. 2003;46:666-9.
26. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci USA. 2006;103:7154-8.
27. Kanatani A, Mashiko S, Murai N, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology. 2000;141:1011-6.
28. Turnbull AV, Ellershaw L, Masters DJ, et al. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes. 2002;51:2441-9.
29. Kushi A, Sasai H, Koizumi H, et al. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptordeficient mice. Proc Natl Acad Sci USA. 1998;95:15659-64.
30. Pedrazzini T, Seydoux J, Kunstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med. 1998;4:722-6.
31. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med. 1998;4:718-21.
32. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 1996;381:415-21.
33. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310:683-5.
34. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006;4:275-82.
35. James WP, Avenell A, Broom J. Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21(Suppl 3): 24-30.
36. Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res. 1995;3:49-56.
37. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473-83.
38. c: a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199.
39. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev. 2003;4:175-84.
40. Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity. 2007;15:895-905.
41. Dryden S, Wang Q, Frankish HM, Pickavance L, Williams G. The serotonin (5-HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat. Brain Res. 1995;699:12-8.
42. Dryden S, Wang Q, Frankish HM, Williams G. Differential effects of the 5-HT 1B/2C receptor agonist mCPP and the 5-HT1A agonist flesinoxan on hypothalamic neuropeptide Y in the rat: evidence that NPY may mediate serotonin's effects on food intake. Peptides. 1996;:17:943-9.
43. Rogers P, McKibbin PE, Williams G. Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat: possible implications for the anorectic effect of fenfluramine. Peptides. 1991;12:251-5.
44. Grignaschi G, Fanelli E, Scagnol I, Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br J Pharmacol. 1999;127:1190-4.
45. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-46.
46. Mashiko S, Ishihara A, Iwaasa H, et al. Anti-obesity effects of a novel Y5 antagonist in diet-induced obese mice: combination with food restriction or sibutramine. Submitted.
47. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004;58:582-7.
48. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab. 2005;7:47-55.
49. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30:159-67.
50. Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dagar A. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med. 2004;202:173-80.
51. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30:159-67.
52. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002;4:49-55.
53. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab. 2004;17:222-9.